痛风患者的可溶性 C-X-C 趋化因子配体 16 水平升高。
Soluble C-X-C chemokine ligand 16 levels are increased in gout patients.
机构信息
School of Pharmacy, Wenzhou Medical College, Chashan College Park, Wenzhou 325035, China.
出版信息
Clin Biochem. 2012 Nov;45(16-17):1368-73. doi: 10.1016/j.clinbiochem.2012.05.014. Epub 2012 May 22.
OBJECTIVES
Soluble C-X-C chemokine ligand 16 (CXCL16) was shown to recruit polymorphonuclear cells into synovial tissue in gout patients. The aim of this study was to explore the pathophysiological characteristics of CXCL16 in gout patients with or without chronic kidney disease (CKD).
DESIGN AND METHODS
42 gout patients, 22 CKD and 20 healthy subjects were enrolled. Plasma CXCL16 and other biochemical parameters were tested.
RESULTS
Plasma CXCL16 levels in gout subjects with CKD were significantly increased compared with healthy, CKD and gout subjects without CKD. Soluble CXCL16 levels in gout subjects were closely correlated with renal function and lipid profiles, and independently associated with 24h proteinuria, creatinine clearance rate and C-reactive protein.
CONCLUSION
Our data indicated that plasma CXCL16 levels are significantly increased in gout patients with and without CKD, and are independently associated with renal function. Elucidating the pathophysiologcial role of CXCL16 in gout patients requires further study.
目的
可溶性 C-X-C 趋化因子配体 16（CXCL16）被证明可招募多形核细胞进入痛风患者的滑膜组织。本研究旨在探讨有或无慢性肾脏病（CKD）的痛风患者中 CXCL16 的病理生理特征。
设计和方法
纳入 42 例痛风患者、22 例 CKD 患者和 20 名健康受试者。检测血浆 CXCL16 和其他生化参数。
结果
与健康、CKD 和无 CKD 的痛风患者相比，CKD 痛风患者的血浆 CXCL16 水平显著升高。痛风患者的可溶性 CXCL16 水平与肾功能和血脂谱密切相关，且与 24 小时蛋白尿、肌酐清除率和 C 反应蛋白独立相关。
结论
我们的数据表明，有和无 CKD 的痛风患者的血浆 CXCL16 水平显著升高，且与肾功能独立相关。阐明 CXCL16 在痛风患者中的病理生理作用需要进一步研究。
Zotero 插件